Diametric Capital LP Sells 63,489 Shares of Gossamer Bio, Inc. (NASDAQ:GOSS)

Diametric Capital LP reduced its stake in Gossamer Bio, Inc. (NASDAQ:GOSS) by 22.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 223,770 shares of the company’s stock after selling 63,489 shares during the period. Diametric Capital LP’s holdings in Gossamer Bio were worth $202,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its position in shares of Gossamer Bio by 24.2% in the third quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock valued at $380,000 after acquiring an additional 74,920 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in Gossamer Bio by 30.7% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company’s stock worth $1,862,000 after purchasing an additional 442,895 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Gossamer Bio by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company’s stock valued at $1,123,000 after purchasing an additional 13,902 shares during the period. Finally, Monaco Asset Management SAM grew its position in shares of Gossamer Bio by 39.5% during the 4th quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company’s stock valued at $4,859,000 after purchasing an additional 1,520,721 shares in the last quarter. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on GOSS shares. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Gossamer Bio in a research note on Tuesday, March 18th. Wedbush reiterated an “outperform” rating and set a $4.00 price target on shares of Gossamer Bio in a research report on Friday, March 14th.

Gossamer Bio Stock Down 1.6 %

Shares of NASDAQ:GOSS opened at $0.98 on Thursday. The firm has a fifty day moving average of $1.20 and a 200 day moving average of $1.00. Gossamer Bio, Inc. has a 52-week low of $0.50 and a 52-week high of $1.55. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The firm has a market capitalization of $222.34 million, a PE ratio of -3.06 and a beta of 1.86.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.15) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.15). The firm had revenue of $9.38 million during the quarter, compared to analysts’ expectations of $7.02 million. As a group, research analysts anticipate that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.